Inflammation

Liver inflammation ↓ / ALT

Systemic inflammation ↓ / CRP

Lower IL-6/WBC

Liver injury markers

-53 U/L ALT

Lobular inflammation ↓

CRP/IL-6 ↓

anti-inflammatory, -32.7%

glutathione boost, cytokines down

Inflammation↓ CRP/IL-6

Inflammation↓ TNF-α/IL-6

Inflammation↓ CRP -15%

Anti-inflammatory + CRP↓

Allergy/eczema ↓ ~50%

↓AA eicosanoids

↓platelet aggregation

↑EPA/AA ratio

Liver enzymes/inflam ↓

SCFAs/endotoxin/inflam ↓

ALT/CRP down

~50% lower inflammation

Fewer liver enzymes

Lower skin inflammation

-45% MMP-9

Less acne irritation

Inflammation↓ CRP/TNF-α

Inflammation↓ plaques/gingivitis

Inflammation↓ diarrhea/infection

Inflammation ↓ CRP/IL-6

Oxidative stress ↓ MDA

SCFA↑, UC inflammation↓

Butyrate↑, cytokines↓

CRP/WBC ↓

TNF-α/IL-6 ↓

MDA/TAC shift

Infection↓ CRP↓

IL-6/TNF-α↓

SIRS/MOF↓

IL-6/TNF-α/CRP ↓

PGE2/hsCRP ↓

NF-κB/cytokines ↓

CRP/TNF-α ↓

Inflammation ↓ CRP/cytokines

Inflammation ↓ leukotrienes/prostaglandins

Inflammation ↓ gene expression

CRP/IL-6 ↓

sICAM-1/VCAM-1 ↓

COX-2/PGE2 ↓

Lower CRP/TNF-α

↓ inflammatory markers

IL-6/hs-CRP down

Inflammation↓ hsCRP -39%

Oxidative stress↓ ROS/lipid peroxidation

Inflammation markers ↓

CRP -38%

TNF-α/IL-6 ↓

Anti-inflammatory skin flare ↓

CRP, eosinophils ↓

Sensory inflammation ↓

Inflammation ↓ (IFN-γ, CRP, IL-6)

Inflammation ↓ (TNF-α, IL-10)

Cytokines ↓ inflammation

CRP/ET/NO ↓

CRP/IL-6↓

JAK/STAT, TNF-α↓

hs-CRP −0.23

Inflammation ↓; CRP/IL-6

Inflammation ↓; 35%→20%

Fibroinflammation ↓; ALT −4.8%

Inflammation↓ hs-CRP/IL-6

Oxidative stress↓ TAC↑

NF-κB↓ SIRT1↑

Inflammation ↓ hs-CRP -6.8%

Cytokines ↓ TNF-α/IL-6

Endothelial/oxidative ↓

↓ inflammation markers

↓ cytokines/CRP

−64% WOMAC/−67% VAS

CRP/TNF-α ↓

IL-6/hs-CRP ↓

-29%, -47%

Lower TNF/IL-6

Faster clearance, +1.3%

Inflammation ↓ ulcer/colitis

Inflammation ↓ IC/BPS symptoms

Inflammation ↓ gastric injury

Inflammation −42.9 mg/L

Inflammation −3.3 pg/mL

less inflammation, pain

−50% swelling, better healing

lower cytokines, skin redness

Inflammation↓ IL-6/CRP

Inflammation↓ TNF-α/IL-10

+140% IL-10

Lower CRP/endotoxin

Gut inflammation repair

↓CRP -5.9 mg/L

Skin inflammation ↓

IL-17A ↓4.4-fold

CRP/TNF-α ↓

PGE2 ↓

Lower cytokines, markers

Skin/gum inflammation ↓

Acute postmeal inflammation ↓

IL-6/CRP↓, SAA−24.5%

NOX/ROS↓, MMP-2/9↓

↓ IL-6, hs-CRP

↓ IL-4, 32%

Inflammation genes −3,422

CRP/IL‑6/TNF‑α ↓

Adhesion markers ↓

Lower inflammation markers

IL-6/CRP/LEU ↓

Reduced tissue inflammation

TNF-α/CRP ↓

IL-6/leptin ↓

MDA/endothelial ↓

LDL/CRP ↓20-30%

Inflammatory markers ↓

Inflammation/itch ↓; hydration ↑

Pain/resolution improved: +98%/96%

URTI episodes ↓: 39 vs 64

↓IL-6/TNF-α

↓CRP/ESR

Oral inflammation −25.6%

Systemic inflammation, CRP

Inflammation ↓, markers

Inflammation −53%, immune cells

Inflammation ↓, symptoms

Inflammation↓ LPS

Cytokines↓ TGF‑β1↑

Akkermansia↑; LPS↓

Joint pain/function -26%

Inflammation markers ↓

Systemic inflammation ↓

Tear cytokines ↓

CRP -30.9%

↓ IL-6/CRP/lymphocytes

↓ gingival inflammation

↓ TNF-α/hsCRP

↓ inflammatory genes

IL-6/CRP ↓

CRP -7.1

Inflammation markers ↓

ESR/CRP↓, IL-6↓, MPO↓

CRP/IL-6/TNFα ↓

Oxylipins/oxLDL ↓

IL-6/IL-8/TNF-α ↓

CRP/IL-8 ↓

Lower hs-CRP

↓6.8%

↓26.8%

Inflammation markers down

TNF-α, ICAM-1

hs-CRP down

Systemic inflammation ↓ CRP

Local gingival inflammation ↓ IL-1β/PGE2/MMP-8

Inflammation markers ↓

CRP/cytokines ↓

MPO -75%

↓TNF-α/IL-1β

↓ESR/hsCRP

Inflammation down: acne, gum

Inflammation down: ARDS, neutrophils

Inflammation down: LTB4 -50%

Gut recovery; CRP↓

UV redness↓

Inflammation ↓ CRP/IL-18

Immune markers altered

↓ IL-6/CRP, MPO

↓ IL-8/leukotrienes

Inflammation+joint pain -0.52

Inflammation+colon response +12%

IL-6, TNF-α ↓

IL-6 ↓ (subgroup)

IL-6 -

Oxidative stress ↓

Oral inflammation ↓

Eye inflammation ↓

Edema/symptoms ↓; -12.9%

Limb size/symptoms ↓

↓IL-6/IL-8, SCORAD

↓CRP −10.5 mg/L

Inflammation ↓ IL-6, F2-iso

Inflammation ↓ fibrinogen

Inflammation ↓ hs-CRP

NE/IL-6 ↓

NLRP3/IL-1 ↓

Inflammation down: CRP/ESR

TNF-α −67%, joints/remission

Pain/function improved

Inflammation ↓ IL-6/TNF-α

CRP/ESR ↓; symptoms ↓

Gut bacteria ↑; SCFAs ↑

Inflammation: hs-CRP -24%

Inflammation: UAS7 improved

Inflammation ↓ CRP -1.94

Inflammation ↓ markers

Inflammation ↓ healing score

Inflammation/immune ↓

Markers+symptoms

CBD/THC: strong ↓

CRP/MMPs ↓

MCP-1 ↓

Pain/bleeding down

CRP/IL-1/TNF-α down

↓ TNF-α, cytokines

↓ plaque/bleeding, bacteria

Inflammation down; hs-CRP

Cytokines down; IL-6

PGD2/symptoms down

Inflammation markers down

Pain/joint scores down

CRP/ESR/RF/CCP-Ab ↓

↓ pain/PGE2 ~25%

↓ IL-1β/IL-6/IL-8

Anti-inflammatory markers ↓

Pain/swelling ↓ 37%

Pain/function ↓

IL-6/CRP ↓

-10 tabs/week

CRP −1.03; inflammation down

Inflammation attenuated; markers improved

CRP ↓, IL-2 ↓

Acylcarnitines/ceramides ↓, CRP ↓

Anti-inflammatory shift

DAS28 -1.08

IL-6 -69%

Lower inflammation markers

+34.1% NK activity

Reduced oxidative stress

Gastric inflammation ↓; H. pylori

IL-6/TNF-α ↓; inflammation

MDA ↓; gastric inflammation

Inflammation ↓ IL-6, hsCRP

Inflammation ↓19%, hsCRP lower

Oxidative stress ↓

T-cell anti-inflammatory shift

Pain/function improves

Airway inflammation drops

Inflammation ↓ IL-10 +2.2

Oral inflammation ↓ PI/BOP

Gingival inflammation ↓ bacteria

Staph/toxin↓, IL-8↓

Colonization↓, severity↓

Inflammation ↓: CRP/TNF‑α

Inflammation ↓: PGE2/COX‑2

Inflammation ↓: IL‑6/TGF‑β

↓ JAK/STAT, autophagy

↓ skin inflammation ~37%

↓ lung inflammation, faster recovery

Inflammation↓ hs-CRP -6.8%

NLRP3/IL-1↓

↓ inflammatory markers

immune shift

hs-CRP ↓

Inflammation markers ↓

hs-CRP ↓11%

LDL-C/TG ↓

TNF-α ↓

hs-CRP 3.1→1.2

IL-6 rise blunted -42%

Glucose/IR improved

Heart rate lowered -4%

hs-CRP, TNF-α ↓

IL-6, ~15% ↓

↓ hs-CRP, TNF-α

↓ prostaglandins, hs-CRP

CRP ↓1.1 mg/L

Inflammatory markers ↓

UC: symptoms -20%, fatigue

Crohn’s: stool freq, pain +17%

Symptoms -33.5%/-57%

IL-10 up; TNF-α/IL-13 high

IL-6/CRP ↓

Homocysteine ↓

Pain, joints ↓53%

TNF-alpha inhibition

Pain ↓53%

Inflammation markers ↓

Joint scores ↓

20-HETE -30%

RA inflammation ↓

Less phlebitis, +20.3% success

Vessel diameter +3.57 mm

CRP −23%; urate −37%

UACR/CRP lower; fewer flares

IL-6/8 down ~55-76%

IL-10 up ~266%

hs-CRP -15%

lipids down 20-41%

Colitis score, TNF-α ↓

ESR, fibrinogen, IL-6 ↓

Swelling reduced, day2

Mouth opening improved, 73%

↓ inflammatory markers

↓ TG/VLDL

ALT, GGT lower

ceramide 14:0 down

itching, dyspareunia, dysuria

greater symptom decrease

hs-CRP/TNF-α ↓

IL-6 ↓

PCR clearance; hs-CRP -12.4x

IL-6/TNF-α lower

Inflammation scores -1.59

Healing +54.67%

Pain/opioid ↓

Analgesic need ↓

Lower TNF-α/ROS

CRP −20.8%

Lesions -82.3%, relapses

Demodex -more reduction

Pain/analgesic ↓

Glucose/weight ↓

Relapse, lesions, disability

Cognition, MSFC, EDSS

Pain/disability ↓

WOMAC total ↓

Oxidative stress ↓

BMI ↓

↓ cortisol/NEFA

↓ haptoglobin

Erosion −44 vs −58.5

Pain −3, equal

hs-CRP ↓

TNF-α/IL-6 ↓

Pain ↓ -5.23

Flow/QOL changes

↓ inflammation markers

− glucose, LDL, HOMA-IR

Knee pain, stiffness

Gum inflammation −55%

Slough down; healing unchanged

Dressing changes -week 12

PASI ↓ greater

Metabolic markers improved

Erythema, SCORAD ↓

No adverse events

NFκB/MAPK↓

Insulin signaling↓

Inflammation down, IL-6 -2.0

Steatosis/ALT down, HOMA-IR down

CRP -59%; inflammation down

ALT lower; less inflammation

Lower nitrite, NOX2, iNOS

BDNF decreased dose-dependently

CRP -2.45 mg/L

AGEs -0.99 units

hs-CRP, IL-6/8 ↓

ALT/AST, HFF ↓